Big Pharmaceutical Companies' Revenues to Be Slashed as a Result of Expiring Patents
The Paragon Report Provides Stock Research on Pfizer and Johnson & Johnson
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 04/30/12 -- The Pharmaceutical Industry currently finds itself in a major dilemma as revenues are expected to be slashed as a result of expiring patents. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. The Obama administration is currently analyzing a proposal in which the exclusivity period for biologics would be cut down by 5 years. The Paragon Report examines investing opportunities in the Drug Manufacturers - Major Industry and provides equity research on Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ).
Access to full reports can be found at:
Mergers & Acquisitions are expected to pick up in 2012 as companies to look to make up for loss revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development. "Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.
Paragon Report releases regular market updates on the Drug Manufacturers - Major Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Pfizer's multi-billion-dollar drug Lipitor lost patent protection in November 2011. The company's board of directors declared a 22-cent second-quarter 2012 dividend on the company's common stock, payable June 5, 2012, to shareholders of record at the close of business on May 11, 2012. Pfizer is expected to report 2012 first quarter earnings on Tuesday, May 1.
Johnson & Johnson, the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes Inc., a premier global manufacturer of orthopedic devices, recently announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for $21.3 billion. Upon completion of this transaction, Synthes and the DePuy Companies of Johnson & Johnson together will comprise the largest business within the Medical Devices and Diagnostics segment of Johnson & Johnson.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.04.2012 - 12:20 Uhr
Sprache: Deutsch
News-ID 140489
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Big Pharmaceutical Companies' Revenues to Be Slashed as a Result of Expiring Patents"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
